Insilico Medicine's Inclusion in MSCI Small Cap Index Marks a Major Milestone for AI-Driven Drug Discovery

Insilico Medicine Takes a Significant Step into MSCI Global Small Cap Indexes

In a groundbreaking announcement made on August 17, 2026, Insilico Medicine, a clinical-stage drug discovery firm driven by generative artificial intelligence (AI), revealed its upcoming inclusion in the MSCI Global Small Cap Indexes administered by Morgan Stanley Capital International (MSCI). This significant change will officially take effect at the close of trading on August 31, 2026.

Being recognized by MSCI, a prestigious name in global index provision, is a testament to Insilico's robust business model and core competitive advantages. The MSCI Global Small Cap Indexes aim to reflect the performance of a diversified array of sectors within small-cap companies across both developed and emerging markets. This endorsement from the capital markets signifies an increasing acknowledgment of Insilico's potential for future commercialization and innovation.

The Impact of Index Inclusion

The inclusion in the MSCI Index is poised to expand Insilico Medicine's visibility on a global scale significantly. The elevation to this index is expected to attract passive capital inflows, thereby enhancing liquidity for trading its stocks. With the ongoing trend of institutional investors utilizing MSCI indexes as benchmarks for investments, this recognition could be crucial for the company's growth trajectory.

Ever since its listing on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, Insilico has garnered attention within the investment community. Notably, the firm has received positive ratings from 13 leading global brokerage firms, including high-profile establishments such as Morgan Stanley, HSBC, and J.P. Morgan. Many of these firms have projected target prices as high as HKD 100, underlining strong market sentiment towards the stock.

The confidence in Insilico's capabilities has been further solidified by its profit alert issued on July 9, 2026, in which the company forecasted first-half revenues ranging between USD 102.5 million to USD 106.5 million. This announcement was met with positive reactions in the stock market, leading to nearly a 40% increase in research coverage in just one month.

Previous Index Achievements

Insilico Medicine's journey in the capital markets has been commendable, already securing spots in several major indices before this latest MSCI inclusion. Such accolades include membership in the China Securities Index Series, the Hang Seng Composite Index, and the FTSE Global Small Cap Index among others. Each milestone enhances the firm’s profile, paving the way for future growth.

Pioneering AI in Drug Discovery

Founded with a mission to transform the pharmaceutical landscape, Insilico Medicine strives to harness the power of AI and automation in the drug discovery process. The company is focused on addressing various unmet medical needs, such as those associated with fibrosis, oncology, immunology, and metabolic disorders. Its innovative solutions aim at accelerating drug discovery while providing expansive AI applications across diverse fields such as agriculture and veterinary medicine.

Spanning multiple healthcare dimensions, Insilico Medicine is set to redefine the landscape of pharmaceutical innovation, combining advanced technology with deep expertise in biotechnology.

As the company continues to push the boundaries of drug discovery, its inclusion in the MSCI Global Small Cap Indexes marks a pivotal point in its journey. As Insilico Medicine lays the groundwork for further achievements, investors and stakeholders alike remain optimistic about its promising future.

For more on Insilico Medicine, visit www.insilico.com.